All lobbying filings
ULTRAGENYX PHARMACEUTICAL INC.
Lobbying for ULTRAGENYX PHARMACEUTICAL INC. · Pharmaceuticals
Filing
Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 17, 2026
Expenses
$440,000.00
What this organization spent lobbying with its own staff.
Reported using A: the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
California
Government bodies contacted
3
Lobbying activity
3
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.
Issues related to drug development, access and reimbursement for rare and ultra rare diseases.